

GLAXOSMITHKLINE PLC

Form 6-K

May 06, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending May 2011

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held in Ordinary Share ADRs within the US Retirement Savings Plan ("The Plan"), of GlaxoSmithKline plc, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 6 May 2011 of an increase in the notional allocation of Ordinary share ADRs on 5 May 2011 at a price of \$42.87 per ADR:-

| Director/PDMR | Number of Shares | Connected Person | Number of Shares |
|---------------|------------------|------------------|------------------|
| Dr M M Slaoui | 9 | Dr K Slaoui | 7 |
| Mr W C Louv | 15 | - | - |
| Dr D Pulman | 27 | - | - |
| Mr E J Gray | 21 | - | - |
| Ms D Connelly | 1 | - | - |

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).

V A Whyte
Company Secretary

6 May 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: May 6, 2011

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc